title: MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer.
abstract: BACKGROUND
  MicroRNAs are small non-coding RNAs that are involved in the post-transcriptional negative regulation of mRNAs. MicroRNA 510 (miR-510) was initially shown to have a potential oncogenic role in breast cancer by the observation of its elevated levels in human breast tumor samples when compared to matched non-tumor samples. Few targets have been identified for miR-510. However, as microRNAs function through the negative regulation of their direct targets, the identification of those targets is critical for the understanding of their functional role in breast cancer.
  
  
  METHODS
  Breast cancer cell lines were transfected with pre-miR-510 or antisense miR-510 and western blotting and quantitative real time PCR were performed. Functional assays performed included cell growth, migration, invasion, colony formation, cytotoxicity and in vivo tumor growth. We performed a PCR assay to identify novel direct targets of miR-510. The study focused on peroxiredoxin 1 (PRDX1) as it was identified through our screen and was bioinformatically predicted to contain a miR-510 seed site in its 3' untranslated region (3'UTR). Luciferase reporter assays and site-directed mutagenesis were performed to confirm PRDX1 as a direct target. The Student's two-sided, paired t-test was used and a P-value less than 0.05 was considered significant.
  
  
  RESULTS
  We show that miR-510 overexpression in non-transformed and breast cancer cells can increase their cell growth, migration, invasion and colony formation in vitro. We also observed increased tumor growth when miR-510 was overexpressed in vivo. We identified PRDX1 through a novel PCR screen and confirmed it as a direct target using luciferase reporter assays. The reintroduction of PRDX1 into breast cancer cell lines without its regulatory 3'UTR confirmed that miR-510 was mediating its migratory phenotype at least in part through the negative regulation of PRDX1. Furthermore, the PI3K/Akt pathway was identified as a positive regulator of miR-510 both in vitro and in vivo.
  
  
  CONCLUSIONS
  In this study, we provide evidence to support a role for miR-510 as a novel oncomir. We show that miR-510 directly binds to the 3'UTR of PRDX1 and blocks its protein expression, thereby suppressing migration of human breast cancer cells. Taken together, these data support a pivotal role for miR-510 in breast cancer progression and suggest it as a potential therapeutic target in breast cancer patients.
authors: Qi J
authors: QJ
authors: Guo
authors: Jamie N
authors: JN
authors: Mills
authors: Savannah G
authors: SG
authors: Bandurraga
authors: Lourdes M
authors: LM
authors: Nogueira
authors: Natalie J
authors: NJ
authors: Mason
authors: E Ramsay
authors: ER
authors: Camp
authors: Amanda C
authors: AC
authors: Larue
authors: David P
authors: DP
authors: Turner
authors: Victoria J
authors: VJ
authors: Findlay
mesh_terms: D020413:3' Untranslated Regions; D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D004195:Disease Models, Animal; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D010084:Oxidation-Reduction; D054464:Peroxiredoxins / Q000235:genetics* / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D015398:Signal Transduction; D047368:Tumor Burden; D014410:Tumor Stem Cell Assay; D023041:Xenograft Model Antitumor Assays
chemical_list: D020413:3' Untranslated Regions; C532745:MIRN510 microRNA, human; D035683:MicroRNAs; D012333:RNA, Messenger; D054464:Peroxiredoxins; D051057:Proto-Oncogene Proteins c-akt
references: Mol Cancer Ther. 2008 Dec;7(12):3655-60
references: 19074842
references: RNA. 2008 Nov;14(11):2440-51
references: 18824511
references: Hum Mol Genet. 2008 Oct 1;17(19):2967-77
references: 18614545
references: Oncogene. 2006 Oct 9;25(46):6188-96
references: 17028598
references: Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
references: 12434020
references: Nature. 2008 Jan 10;451(7175):147-52
references: 18185580
references: Cell Immunol. 2010;260(2):70-4
references: 19954774
references: Curr Opin Pharmacol. 2007 Aug;7(4):375-80
references: 17616437
references: Cancer Res. 2008 Oct 15;68(20):8499-506
references: 18922924
references: Cancer Res. 2005 Aug 15;65(16):7065-70
references: 16103053
references: Nat Rev Genet. 2004 May;5(5):396-400
references: 15143321
references: Trends Genet. 2008 Oct;24(10):489-97
references: 18778868
references: J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):97-108
references: 21494783
references: Breast Cancer Res. 2011;13(6):228
references: 22114869
references: Cell Cycle. 2009 Dec 15;8(24):4072-8
references: 19923889
references: Cancer Invest. 2012 Jan;30(1):38-47
references: 22236188
references: Nat Rev Cancer. 2006 Apr;6(4):259-69
references: 16557279
references: Int J Dev Biol. 2011;55(7-9):889-97
references: 22161844
references: Oncogene. 2006 Oct 9;25(46):6220-7
references: 17028602
references: Breast Cancer Res. 2011;13(6):226
references: 22078097
references: Nat Rev Genet. 2004 Jul;5(7):522-31
references: 15211354
references: Nat Cell Biol. 2008 Feb;10(2):202-10
references: 18193036
references: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references: 2359136
references: Nature. 2003 Jul 31;424(6948):561-5
references: 12891360
references: EMBO J. 2009 May 20;28(10):1505-17
references: 19369943